Pavel Klener (P Klener)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 25

Top Venues

Blood advances

Cancers

Blood

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Jana Karolova, D Kazantsev, M Svatoň, L Tušková, K Forsterová, D Maláriková, K Benešová, T Heizer, A Dolníková, M Klánová, L Winkovska, K Svobodová, J Hojný, E Krkavcová, E Froňková, Z Zemanová, M Trněný, Pavel Klener
Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy. American journal of hematology (2023)
Anja Schmitt, Melanie Grimm, Nina Kreienkamp, Hannah Junge, Jan Labisch, Laurentz Schuhknecht, Caroline Schönfeld, Elsa Sophie Görsch, Alessia Tibello, Kerstin Menck, Annalen Bleckmann, Claudia Lengerke, Frank Rosenbauer, Michael Grau, Mattia Zampieri, Klaus Schulze-Osthoff, Pavel Klener, Alexandra Dolnikova, Georg Lenz, Stephan Hailfinger
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood (2023)
Tomas Etrych, Alena Braunova, David Zogala, Lukas Lambert, Nicol Renešová, Pavel Klener
Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas. Cancers 14 (3) (2022)
Radek Jakša, Jana Karolová, Michael Svatoň, Dmitry Kazantsev, Martina Grajciarová, Eva Pokorná, Zbynek Tonar, Magdalena Klánová, Lucie Winkowska, Diana Maláriková, Petra Vočková, Kristina Forsterová, Nicol Renešová, Alexandra Dolníková, Kristýna Nožičková, Pavel Dundr, Eva Froňková, Marek Trněný, Pavel Klener
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Laboratory investigation; a journal of technical methods and pathology 102 (9) (2022)
Chiara Rusconi, Chan Yoon Y Cheah, Toby Andrew Eyre, David Tucker, Pavel Klener, Eva Giné, Lara Crucitti, Cristina Muzi, Sara Iadecola, Gabriele Infante, Sophie Bernard, Rebecca L Auer, Chiara Pagani, Monika Duglosz-Danecka, Heidi Mocikova, Tom van Meerten, Emanuele Cencini, Ana Marin-Niebla, Michael E Williams, Piera Angelillo, Paolo Nicoli, Annalisa Arcari, Lucia Morello, Donato Mannina, Orsola Vitagliano, Roberto Sartori, Annalisa Chiappella, Roberta Sciarra, Piero Maria Stefani, Martin Dreyling, John Francis Seymour, Carlo Visco
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood 140 (17) (2022)
Anja Schmitt, Wendan Xu, Philip Bucher, Melanie Grimm, Martina Konantz, Heike Horn, Myroslav Zapukhlyak, Philipp Berning, Marc Brändle, Mohamed-Ali Jarboui, Caroline Schönfeld, Karsten Boldt, Andreas Rosenwald, German Ott, Michael Grau, Pavel Klener, Petra Vockova, Claudia Lengerke, Georg Lenz, Klaus Schulze-Osthoff, Stephan Hailfinger
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL. Blood 138 (10) (2021)
Magdalena Klanova, Dmitry Kazantsev, Eva Pokorna, Tomas Zikmund, Jana Karolova, Matej Behounek, Nicol Renesova, Dana Sovilj, Cristina D Kelemen, Karel Helman, Radek Jaksa, Ondrej Havranek, Ladislav Andera, Marek Trneny, Pavel Klener
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas. Molecular cancer therapeutics (2021)
Pavel Klener, Dana Sovilj, Nicol Renesova, Ladislav Andera
BH3 Mimetics in Hematologic Malignancies. International journal of molecular sciences 22 (18) (2021)
Pavel Klener
Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. Expert opinion on therapeutic targets 24 (10) (2020)
Aleš Obr, Pavel Klener, Tomas Furst, Eva Kriegova, Zuzana Zemanova, Helena Urbankova, Andrea Jirkuvova, Anna Petrackova, Diana Malarikova, Kristina Forsterova, Barbora Cudova, Lenka Sedlarikova, Adela Berkova, Nela Kasalova, Tomas Papajik, Marek Trneny
A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. British journal of haematology 191 (5) (2020)
Pavel Klener, Magdalena Klanova
Drug Resistance in Non-Hodgkin Lymphomas. International journal of molecular sciences 21 (6) (2020)
Magdalena Klanova, Pavel Klener
BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas. Cancers 12 (4) (2020)
Diana Malarikova, Adela Berkova, Aleš Obr, Petra Blahovcova, Michael Svatoň, Kristina Forsterova, Eva Kriegova, Eva Prihodova, Lenka Pavlistova, Anna Petrackova, Zuzana Zemanova, Marek Trneny, Pavel Klener
Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. Cancers 12 (8) (2020)
Petra Vockova, Jan Molinsky, Magdalena Klanova, Josef Karban, Martin Spacek, Ondrej Havranek, Kristyna Kupcova, Dmitry Kazantsev, Marek Trneny, Pavel Klener
CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement. Leukemia & lymphoma 62 (4) (2020)
Robert Pytlik, Kamila Polgarova, Jana Karolova, Pavel Klener
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines 8 (4) (2020)
Pavel Klener
Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. International journal of molecular sciences 20 (18) (2019)
Elizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, Johanna Richter, Yohannes Gebreselassie, Matthew J Carter, Jana Karolova, Michael Svaton, Karel Helman, Nicola J Weston-Bell, Laura Karydis, Chris T Williamson, Georg Lenz, Jeremy Pettigrew, Curtis Harwig, Freda K Stevenson, Mark S Cragg, Francesco Forconi, Andrew J Steele, Jennifer Cross, Lloyd Mackenzie, Pavel Klener, Graham Packham
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (7) (2019)
Dana Prukova, Ladislav Andera, Zuzana Nahacka, Jana Karolova, Michael Svaton, Magdalena Klanova, Ondrej Havranek, Jan Soukup, Karla Svobodova, Zuzana Zemanova, Diana Tuskova, Eva Pokorna, Karel Helman, Kristina Forsterova, Mariana Pacheco-Blanco, Petra Vockova, Adela Berkova, Eva Froňková, Marek Trneny, Pavel Klener
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (14) (2019)
Pavel Klener, Eva Fronkova, Marketa Kalinova, David Belada, Kristina Forsterova, Robert Pytlik, Petra Blahovcova, Martin Simkovic, David Salek, Heidi Mocikova, Vit Prochazka, Andrea Janikova, Martina Vaskova, Ester Mejstrikova, Roman Kodet, Jan Trka, Marek Trneny
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. Hematological oncology 36 (5) (2018)
Pavel Klener, David Salek, Robert Pytlik, Heidi Mocikova, Kristina Forsterova, Petra Blahovcova, Vit Campr, Vit Prochazka, Ales Obr, Radek Jaksa, Jana Kuntscherova, Ludmila Boudová, Roman Kodet, Andrea Janikova, Marek Trneny
Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. American journal of hematology 94 (2) (2018)
Pavel Klener, Eva Fronkova, David Belada, Kristina Forsterova, Robert Pytlik, Marketa Kalinova, Martin Simkovic, David Salek, Heidi Mocikova, Vit Prochazka, Petra Blahovcova, Andrea Janikova, Jana Markova, Ales Obr, Adela Berkova, Jozef Kubinyi, Martina Vaskova, Ester Mejstrikova, Vit Campr, Radek Jaksa, Roman Kodet, Kyra Michalova, Jan Trka, Marek Trneny
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematological oncology 36 (1) (2017)

Pavel Klener.css-eqlu8i{font-size:small;padding-left:4px;} (P Klener)

Publication Activity (10 Years)

Top Topics

Top Venues

Pavel Klener (P Klener)